M. Hohenboken

发表

Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.

P. Chanthavanich, M. Bulitta, E. Anderson, 2019, The Pediatric infectious disease journal.

Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults

M. Hohenboken, Daphne C Sawlwin, E. Versage, 2021, Vaccines.

Safety and Immunogenicity of MF59-Adjuvanted Cell Culture–Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly

S. Shakib, S. Frey, P. Richmond, 2019, Open Forum Infectious Diseases.

Identification and localization of glucagon-related peptides in rat brain.

R. Dinerstein, M. Hohenboken, H. Tager, 1980, Proceedings of the National Academy of Sciences of the United States of America.

The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.

D. Sack, S. Gahagan, G. Calandra, 1991, The New England journal of medicine.

Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age

T. Odrljin, M. Nissen, T. Nolan, 2014, Human vaccines & immunotherapeutics.

Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.

N. Kanesa-thasan, M. Hohenboken, P. Jaehnig, 2015, The Journal of infectious diseases.

Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects.

P. Chanthavanich, M. Hohenboken, E. Versage, 2021, Vaccine.

Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to One Year After Immunization with a Pandemic A/H1N1 Influenza Vaccine in Children 3 to < 9 Years of Age.

N. Kanesa-thasan, M. Hohenboken, S. Christensen, 2012, The Pediatric infectious disease journal.

High titer glucagon antisera.

M. Hohenboken, H. Tager, J. Markese, 1977, Endocrinology.

Outcomes in Pregnant Persons Immunized with a Cell-Based Quadrivalent Inactivated Influenza Vaccine: A Prospective Observational Cohort Study

J. Albano, H. Tilson, M. Hohenboken, 2022, Vaccines.

A Prospective Cohort Study on Pregnancy Outcomes of Persons Immunized with a Seasonal Quadrivalent Inactivated Influenza Vaccine during Pregnancy

J. Albano, M. Hohenboken, J. Oberyé, 2022, Vaccines.

Vaccination as infection control: a pilot study to determine the impact of Staphylococcus aureus vaccination on nasal carriage.

K. Edwards, T. Talbot, C. Creech, 2009, Vaccine.

A Cell Culture–Derived MF59-Adjuvanted Pandemic A/H7N9 Vaccine Is Immunogenic in Adults

P. Dormitzer, G. Della Cioppa, N. Kanesa-thasan, 2014, Science Translational Medicine.

Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients.

K. Schulman, V. Fowler, S. Reed, 2009, Clinical journal of the American Society of Nephrology : CJASN.

Persistent urinary antigen excretion in infants vaccinated with Haemophilus influenzae type b capsular polysaccharide conjugated with outer membrane protein from Neisseria meningitidis.

M. Santosham, M. Hohenboken, J. Goepp, 1992 .

Safety and Immunogenicity of Cell-Based Quadrivalent Influenza Vaccine: A Randomized Trial.

M. Hohenboken, Robert J. Jeanfreau, D. Molrine, 2022, Pediatrics.

Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.

T. Odrljin, N. Chiu, C. Chiu, 2014, Vaccine.

Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects

M. Hohenboken, James T Peterson, E. Versage, 2022, Vaccines.

Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to 1 Year After Immunization With a Pandemic A/H1N1 Influenza Vaccine in Children 3 to <9 Years of Age

N. Kanesa-thasan, M. Hohenboken, S. Christensen, 2012, The Pediatric infectious disease journal.

Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and without Underlying Medical Conditions

M. Hohenboken, E. van Twuijver, Tino F. Schwarz, 2024, Vaccines.

Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture–derived H5N1 (aH5n1c) influenza vaccine in adults and older adults

Sharon Frey, M. Hohenboken, E. van Twuijver, 2023, Human vaccines & immunotherapeutics.